• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

In The Literature: TNF-α Antagonists in RA Patients Reduces Cancer Risk

Article

A Taiwan study found a significantly reduced risk of cancer among RA patients on biologics.

A nationwide study, conducted in Taiwan between 1999-2011 using the Taiwan National Health Insurance Research Database, compared the risk of cancer diagnosis in patients with rheumatoid arthritis who were administered the TNF-α antagonists versus non-biological disease-modifying anti-rheumatic drugs (nbDMARDs). The study identified a significantly reduced incidence rate of cancer among patients using biologics, and modified Cox proportional hazards analysis showed a much lower risk in the biologics cohort of 4426 users of TNF-α antagonists (HR 0.63, 95% CI 0.49—0.80, P <.001). There was however an increased risk of hematological cancers in the biologics cohort.

Link to the paper in Arthritis Research and Therapy: http://bit.ly/1uVJHWe

Related Videos
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
dr linda bosserman
dr andrew leitner
Glenn Balasky during a video interview
dr joseph alvarnas
dr joseph alvarnas
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.